In advanced non-small cell lung cancer (NSCLC) patients harboring a PD-L1 tumor proportion score (TPS) of ≥50%, immunotherapy alone has shown a clear benefit over chemotherapy doublets in first-line settings [28]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.